Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCD1 | P51178 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.55 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.49 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486814 | 0.98 | PLCD1 (0.56) | PLCD1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL2028171 | 0.96 | PLCD1 (0.55) | PLCD1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL486900 | 0.94 | F2 (0.53) | PLCD1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL20500226 | 0.90 | PLCD1 (0.48) | PLCD1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL12989865 | 0.88 | CNR2 (0.68) | PLCD1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL30165784 | 0.87 | CNR2 (0.66) | PLCD1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL10140249 | 0.87 | CNR2 (0.66) | PLCD1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL28352827 | 0.86 | TDP1 (0.50) | PLCD1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1270689 | 0.86 | PLCD1 (0.44) | PLCD1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL487698 | 0.86 | PLCD1 (0.44) | PLCD1F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | DIASOME PHARMACEUTICALS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | claimed |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-08-25 | — | — | US | claimed |
| US-9034372-B2 | Lipid construct for delivery of insulin to a mammal | SDG, INC. (US) | 2015-05-19 | — | — | US | claimed |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2025-09-18 | — | — | US | disclosed |
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-9943602-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9145453-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140243430-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130267462-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. | 2013-10-10 | — | — | US | disclosed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | SDG, INC. | 2010-04-01 | — | — | US | disclosed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080773-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | PLCD1 4686/4885F2 2252/4885PRSS1 1301/4885 |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | PLCD1 4370/4885F2 2636/4885PRSS1 981/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | PLCD1 281/4885F2 3128/4885PRSS1 2283/4885 |
| US-20130183270-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, FABP1, LIPC | PLCD1 4686/4885F2 2252/4885PRSS1 1301/4885 |
| US-20100310599-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | PLCD1 2823/4885F2 1894/4885PRSS1 4150/4885 |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | GPR119, INSR, FABP1 | PLCD1 1098/4885F2 3168/4885PRSS1 4590/4885 |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | PLCD1 4370/4885F2 2636/4885PRSS1 981/4885 |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | PLCD1 4370/4885F2 2636/4885PRSS1 981/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | PLCD1 4631/4885F2 2357/4885PRSS1 845/4885 |
| US-20140243430-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, LIPC, FABP6 | PLCD1 2823/4885F2 1894/4885PRSS1 4150/4885 |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | PLCD1 4370/4885F2 2636/4885PRSS1 981/4885 |
| US-20100247625-A1 | Orally Bioavailable Lipid-Based Constructs | FABP2, LIPC, FABP6 | PLCD1 2823/4885F2 1894/4885PRSS1 4150/4885 |
| US-20130267462-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | PLCD1 1602/4885F2 2597/4885PRSS1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.